EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Applications of Tissue-Free Molecular Residual Disease (MRD) in Colorectal Cancer—Real-World Utilization and Case Series in Asian and Middle Eastern Patients

Yao-Yu Hsieh, Viraj Lavingia, Gali Perl, Ching-Tso Chen, Feng-Che Kuan, Sai Vivek, Sandra San Hsing, Suyog Jain

International Journal of Translational Medicine · 30.03.2026 · 6 (2) · 12

DOI: 10.3390/ijtm6020012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Translational Medicine, online erschienen am 30.03.2026. Verfasst von Yao-Yu Hsieh und 7 weiteren Autor:innen. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite well-established treatment and follow-up protocols for the management of colorectal cancer patients, recurrences are frequent. Post curative therapy, ctDNA-based molecular residual disease assessment has the ability to stratify patients into higher and lower risks of recurrence. Large-scale clinical trials are necessary to establish utility at a broad level, but physicians also need real-world evidence and case reports before utilizing MRD testing in routine practice.

Methods

We analyzed real-world utilization patterns of Guardant Reveal in patients with CRC across stages by collating information from the test request form after the test was ordered as a part of routine practice in the AMEA region.

Results

We report that 92% of the tests were utilized for stage II and stage III patients. The timing of the first MRD test order varies between stages, with a higher proportion of tests being ordered within the first 12 weeks of surgery for stage II (71.8%), while for stage III (50%) and stage IV oligometastatic (72%), the first test was ordered after 12 weeks of surgery.

Conclusions

Case reports delineate physicians’ perspectives on actions taken on the basis of MRD test results and outcomes.

Zitieren

APA

Hsieh, Y., Lavingia, V., Perl, G., Chen, C., Kuan, F., Vivek, S., Hsing, S. S., & Jain, S. (2026). Clinical Applications of Tissue-Free Molecular Residual Disease (MRD) in Colorectal Cancer—Real-World Utilization and Case Series in Asian and Middle Eastern Patients. International Journal of Translational Medicine, 6(2), 12. https://doi.org/10.3390/ijtm6020012

Vancouver

Hsieh Y, Lavingia V, Perl G, Chen C, Kuan F, Vivek S, et al. Clinical Applications of Tissue-Free Molecular Residual Disease (MRD) in Colorectal Cancer—Real-World Utilization and Case Series in Asian and Middle Eastern Patients. International Journal of Translational Medicine. 2026;6(2):12. doi:10.3390/ijtm6020012

BibTeX
@article{Hsieh2026,
  author = {Hsieh, Yao-Yu and Lavingia, Viraj and Perl, Gali and Chen, Ching-Tso and Kuan, Feng-Che and Vivek, Sai and Hsing, Sandra San and Jain, Suyog},
  title = {Clinical Applications of Tissue-Free Molecular Residual Disease (MRD) in Colorectal Cancer—Real-World Utilization and Case Series in Asian and Middle Eastern Patients},
  journal = {International Journal of Translational Medicine},
  year = {2026},
  volume = {6},
  number = {2},
  pages = {12},
  doi = {10.3390/ijtm6020012}
}
Kostenlos starten →